Site-specific expression of Cre recombinase in the Oncopig resulted in localized p53 inhibition and KRAS activation; subcutaneous injection of AdCre produced mesenchymal tumors at the injection sites31 in non-immunosuppressed Oncopigs. The gene discussed is KRAS; the disease is mesenchymal cell neoplasm.